A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 34,200 shares of PLRX stock, worth $415,188. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,200
Previous 26,500 29.06%
Holding current value
$415,188
Previous $394,000 6.85%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$10.58 - $15.61 $13.4 Million - $19.8 Million
-1,271,034 Reduced 74.69%
430,712 $4.63 Million
Q1 2024

May 15, 2024

BUY
$14.14 - $19.59 $1.74 Million - $2.41 Million
123,232 Added 7.81%
1,701,746 $25.4 Million
Q4 2023

Feb 14, 2024

BUY
$12.85 - $19.15 $750,902 - $1.12 Million
58,436 Added 3.84%
1,578,514 $28.6 Million
Q3 2023

Nov 14, 2023

SELL
$14.58 - $20.15 $1.35 Million - $1.87 Million
-92,829 Reduced 5.76%
1,520,078 $26.4 Million
Q2 2023

Aug 14, 2023

BUY
$18.12 - $30.56 $9.03 Million - $15.2 Million
498,079 Added 44.68%
1,612,907 $29.2 Million
Q1 2023

May 15, 2023

BUY
$18.73 - $36.26 $2.32 Million - $4.49 Million
123,707 Added 12.48%
1,114,828 $29.7 Million
Q4 2022

Feb 14, 2023

BUY
$17.0 - $25.43 $9.74 Million - $14.6 Million
573,233 Added 137.17%
991,121 $19.2 Million
Q3 2022

Nov 14, 2022

SELL
$7.67 - $24.23 $7.4 Million - $23.4 Million
-965,439 Reduced 69.79%
417,888 $8.73 Million
Q2 2022

Aug 15, 2022

BUY
$4.11 - $8.75 $23,916 - $50,916
5,819 Added 0.42%
1,383,327 $11.1 Million
Q1 2022

May 16, 2022

BUY
$7.01 - $14.1 $283,077 - $569,386
40,382 Added 3.02%
1,377,508 $9.66 Million
Q4 2021

Feb 14, 2022

BUY
$12.27 - $18.26 $107,485 - $159,957
8,760 Added 0.66%
1,337,126 $18.1 Million
Q3 2021

Nov 15, 2021

BUY
$16.48 - $28.98 $2.14 Million - $3.77 Million
129,961 Added 10.84%
1,328,366 $22.4 Million
Q2 2021

Aug 16, 2021

SELL
$28.05 - $37.69 $666,888 - $896,079
-23,775 Reduced 1.95%
1,198,405 $34.9 Million
Q1 2021

May 17, 2021

SELL
$24.52 - $40.23 $247,112 - $405,437
-10,078 Reduced 0.82%
1,222,180 $48.1 Million
Q4 2020

Feb 16, 2021

BUY
$19.89 - $32.99 $56,189 - $93,196
2,825 Added 0.23%
1,232,258 $28 Million
Q3 2020

Nov 16, 2020

SELL
$21.54 - $29.53 $72,094 - $98,836
-3,347 Reduced 0.27%
1,229,433 $27.8 Million
Q2 2020

Aug 14, 2020

BUY
$21.3 - $35.26 $26.3 Million - $43.5 Million
1,232,780 New
1,232,780 $40 Million

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $591M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.